Vingerhoets Claudia, Tse Desmond H Y, van Amelsvoort Therese
Maastricht University, Department of Psychiatry & Psychology, Maastricht, the Netherlands; Amsterdam UMC, University of Amsterdam, Department of Nuclear Medicine, Amsterdam, the Netherlands.
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.
Eur J Med Genet. 2019 Aug;62(8):103705. doi: 10.1016/j.ejmg.2019.103705. Epub 2019 Jun 20.
22q11.2 deletion syndrome (22q11DS) is a genetic disorder caused by a hemizygous microdeletion on the long arm of chromosome 22 and is associated with a high risk for psychosis and cognitive impairment. One of the genes located in the deleted region of 22q11DS is Proline Dehydrogenase (PRODH) which is important for conversion of proline to glutamate. Glutamate is the primary excitatory neurotransmitter and is involved in the pathophysiology of psychosis as well as in cognition. Excessive concentrations are toxic. Possibly, neuroprotective drugs modulating glutamatergic neurotransmission could be effective in treating psychotic symptoms and cognitive enhancement in patients with 22q11DS. Riluzole is a potent anti-glutamatergic drug that reduces glutamatergic neurotransmission. Here we report acute (single dose) and long-term effects of riluzole on glutamate and GABA levels in the anterior cingulate cortex (ACC) and striatum (measured with magnetic resonance spectroscopy, 1H-MRS) as well as on psychotic symptoms and cognitive functioning in a medication-free 23-year old woman with 22q11DS. Patient presented with frequent auditory and visual hallucinations and mild paranoid ideas. The H-MRS measurements showed that after a single dose riluzole (50 mg), glutamate in the ACC and striatum was reduced whereas striatal GABA increased compared to baseline. Strikingly, hallucinations and paranoia disappeared. Therefore, riluzole treatment was initiated and patient was followed up after 18 months of treatment. At follow-up, patient reported no hallucinations or paranoia and several cognitive functions were improved. Furthermore, glutamate concentrations in the ACC and striatum decreased whereas GABA concentrations increased in the striatum but decreased in the ACC. These results suggests that riluzole may be an effective treatment option for psychotic symptoms and cognitive enhancement in 22q11DS. Results warrant replication in a bigger sample.
22q11.2缺失综合征(22q11DS)是一种由22号染色体长臂上的半合子微缺失引起的遗传性疾病,与精神病和认知障碍的高风险相关。位于22q11DS缺失区域的基因之一是脯氨酸脱氢酶(PRODH),它对脯氨酸转化为谷氨酸很重要。谷氨酸是主要的兴奋性神经递质,参与精神病的病理生理过程以及认知过程。浓度过高是有毒的。可能调节谷氨酸能神经传递的神经保护药物对治疗22q11DS患者的精神病症状和认知增强有效。利鲁唑是一种有效的抗谷氨酸能药物,可减少谷氨酸能神经传递。在此,我们报告了利鲁唑对一名23岁未服药的22q11DS女性前扣带回皮质(ACC)和纹状体中谷氨酸和GABA水平(用磁共振波谱1H-MRS测量)的急性(单剂量)和长期影响,以及对精神病症状和认知功能的影响。该患者经常出现听觉和视觉幻觉以及轻度偏执观念。1H-MRS测量显示,单次服用利鲁唑(50毫克)后,ACC和纹状体中的谷氨酸减少,而纹状体中的GABA与基线相比增加。令人惊讶的是,幻觉和偏执消失了。因此,开始了利鲁唑治疗,并在治疗18个月后对患者进行了随访。随访时,患者报告没有幻觉或偏执,并且几项认知功能得到了改善。此外,ACC和纹状体中的谷氨酸浓度降低,而纹状体中的GABA浓度增加,但ACC中的GABA浓度降低。这些结果表明,利鲁唑可能是治疗22q11DS患者精神病症状和认知增强的有效治疗选择。结果有待在更大的样本中进行重复验证。